AVTX is +250% in AH trading. The outgoing CEO of AlmataBio (the private company AVTX is acquiring) is Patrick Crutcher, who used to be a co-moderator of this message board.
This deal is structured as a regular-way merger, but it’s conceptually a reverse-merger insofar as AVTX’s lead asset is the one they just licked up from AlmataBio.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.